Proteomics-inspired precision medicine for treating and understanding multiple myeloma.

ABSTRACT:

Introduction

Remarkable progress in molecular characterization methods has led to significant improvements in how we manage multiple myeloma (MM). The introduction of novel therapies has led to significant improvements in overall survival over the past 10 years. However, MM remains incurable and treatment choice is largely based on outdated risk-adaptive strategies that do not factor in improved treatment outcomes in the context of modern therapies.

Areas covered

This review discusses current risk-adaptive strategies in MM and the clinical application of proteomics in the monitoring of treatment response, disease progression, and minimal residual disease (MRD). We also discuss promising biomarkers of disease progression, treatment response, and chemoresistance. Finally, we w

SUBMITTER: Ho M 

PROVIDER: S-EPMC8372187 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature